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Abstract 
Arry-520 is an advanced drug candidate from the Eg5 inhibitor class undergoing clinical 
evaluation in patients with relapsed or refractory multiple myeloma. Here we show by 
structural analysis that Arry-520 binds stoichiometrically to the motor domain of Eg5 in the 
conventional allosteric loop L5 pocket in a complex that suggests the same structural 
mechanism as other Eg5 inhibitors. We have previously shown that acquired resistance 
through mutations in the allosteric binding site located at loop L5 in the Eg5 structure appears 
to be independent of the inhibitors’ scaffold, which suggests that Arry-520 will ultimately 
have the same fate. When Arry-520 was assessed in two cell lines selected for the expression 
of either Eg5(D130A) or Eg5(L214A) STLC-resistant alleles, mutations previously shown to 
convey resistance to this class of inhibitors, it was inactive in both.  Surprisingly, when the 
cells were challenged with ispinesib, another Eg5 inhibitor, the Eg5(D130A) cells were 
resistant, but those expressing Eg5(L214A) were strikingly sensitive. Molecular dynamics 
simulations suggest that subtle differences in ligand binding and flexibility in both compound 
and protein may alter allosteric transmission from the loop L5 site that do not necessarily 
result in reduced inhibitory activity in mutated Eg5 structures. Whilst we predict that cells 
challenged with Arry-520 in the clinical setting are likely to acquire resistance through point 
mutations in the Eg5 binding site, the data for ispinesib suggests that this resistance 
mechanism is not scaffold independent as previously thought, and new inhibitors can be 
designed that retain inhibitory activity in these resistant cells.    
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Introduction 
Over the last two decades, the role of the kinesin motor protein Eg5 (also known as Kinesin 
Spindle Protein, KSP and coded by the Kif11 gene) in spindle formation and as a target for 
the development of novel antimitotic agents has been intensively investigated (1). Eg5, like 
many other kinesins, uses the chemical energy released by its hydrolysis of ATP to generate 
the force required to move unidirectionally along MTs (2). Eg5 is a plus-end directed motor 
(2) which, through its antiparallel homotetrameric nature (3), is capable of cross-linking 
antiparallel overlapping MTs during mitosis and is responsible for centrosome separation and 
spindle bipolarity (4). Since the discovery of monastrol (5), a small molecule inhibitor of Eg5 
capable of inducing mitotic arrest in cells through the formation of  monoastral spindles and 
the subsequent failure of duplicated centrosomes to separate, a large number of Eg5 inhibitors 
have been developed, with some entering clinical trials (6). 
 
Most Eg5 inhibitors target a specific allosteric site in its motor domain composed of helix 
α2/loop L5 and helix α3 (7), which is approximately 10 Å away from the ATP binding site.  
Binding to this pocket induces a rearrangement of loop L5, which allosterically transmits 
conformational changes in the ATP binding pocket, slowing down ADP release.  As a result, 
Eg5 is trapped in an ‘‘ATP-like’’ conformation and the mechanochemical cycle of the motor 
is inhibited (8),(9),(10). More recently, another group of Eg5 inhibitors has been found to 
bind to a different allosteric pocket of the Eg5 motor domain formed by helices α4 and α6 
(11),(12),(13),(14). 
 
Although a number of loop L5 binding agents have entered clinical trials, results have been 
disappointing across various tumor types (15). One possible explanation for the poor clinical 
efficacy of Eg5 inhibitors in these trials may be the observation that in solid tumours, cells 
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divide more slowly and not at the high rates observed in mice tumour xenografts thus limiting 
the number of mitotic cells responding to Eg5 inhibition during chemotherapy at the 
concentrations administered (16). 
 
Recently however, the Eg5 inhibitor Arry-520 (approved name filanesib; Figure 1a) has 
proved to be effective in phase I and II clinical trials involving patients with soft tissue 
cancers, particularly in those with relapsed or refractory multiple myeloma (17),(18), and has 
since progressed to a phase III clinical trial. Arry-520 has a tolerable safety profile with an 
improved pharmacokinetic  profile compared to other Eg5 inhibitors and encouraging efficacy 
when administrated as a monotherapy or in combination with proteasome inhibitors in 
patients heavily pretreated with other chemotherapeutic agents (19). Furthermore, results from 
clinical trials also indicated a relationship between the expression levels of α-1 acidic 
glycoprotein (AAG) and the efficacy of Arry-520: low levels of AAG in the serum of patients 
were correlated with a better chemotherapeutic index compared to higher AAG levels (19). 
 
The success of Arry-520 against haematological malignancies in the clinic has been linked to 
the lower stability of the Mcl-1 anti-apoptotic protein during mitotic block in these cell types 
(20). Exposure to Arry-520-induced Eg5 inhibition promotes Mcl-1 degradation during 
mitotic block, which diminishes the pro-survival signals and allows the apoptotic pathway to 
be initiated unhindered.  Tumour cells less responsive to Eg5 inhibition have survival signals 
dependent on other members of the anti-apoptotic family such as Bcl-2 or Bcl-XL. These 
proteins exhibit slower degradation profiles during mitotic block compared to Mcl-1, and may 
still be capable of inducing their pro-survival signals in response to Eg5 inhibition and mitotic 
arrest, leading to less efficient cell death in these tumour types (21). 
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Emergence of resistance to any drug treatment for cancer is often encountered in the clinic 
and one would expect the same to occur in tumor cells exposed to anti-Eg5 inhibitors. Whilst 
no clinically relevant Eg5 mutations have been reported to date that are involved in the 
development of resistance clinically, what has been shown in tumour cells constantly exposed 
to Eg5 inhibitors is the adaptation and use of alternative pathways to progress to a bipolar 
spindle.  These include overexpression of other members of the kinesin family such as Kif15 
(22),(23) or reduced expression of proteins such as dynein that oppose Eg5 activity in 
centrosome separation (24). Resistance to inhibitors may also arise through point mutations in 
the Eg5 inhibitor binding pocket (25),(26),(10),(27). Mutations in the helix α2, loop L5 and 
helix α3 allosteric binding site of Eg5 have been shown to confer resistance in cells to 
monastrol and a variety of other loop L5 inhibitors (28) including STLC (29), a compound 
previously identified by our group (30). Notably, we have shown that mutations to specific 
residues in the inhibitor-binding site (including D130A; D130V; D133A and L214A), can 
overcome inhibition by blocking the allosteric communication network to the ATP binding 
site (31). We also demonstrated that these mutations were scaffold independent and can 
confer resistance across different loop L5 binding inhibitors (28). Whether any of these point 
mutations can induce resistance to the advanced clinical candidate Arry-520 is not yet known, 
but the results from our earlier studies suggest that this is possible, which could have 
implications for its clinical success.  
 
To date, the structure of Arry-520 complexed with Eg5 has not been reported. If it binds to 
the loop L5 region like other inhibitors, the potential for resistance to develop is increased. 
The focus of this study was to establish whether Arry-520 was a loop L5 binding allosteric 
inhibitor by determining the structure of the complex, and given its progression to Phase III 
clinical trials, whether resistance is likely via point mutations in the allosteric site that have 
 6 
previously been shown to be scaffold independent. To explore this, we compared the activity 
of Arry-520 with another important Eg5 inhibitor ispinesib in cell lines expressing the STLC-
resistant D130A or L214A alleles of Eg5 in order to evaluate whether resistance could 
develop to these significantly different scaffolds. Ispinesib itself has previously been through 
extensive phase I and phase II clinical trials evaluation (32).  
Our structural data demonstrates that Arry-520 binds to the same helix α2, loop L5 and helix 
α3 allosteric site as ispinesib (33), monastrol (7) and STLC (34). Furthermore, our cell-based 
assays show that cells expressing either the Eg5 D130A or the L214A allele were both 
resistant to Arry-520. However, whilst resistance to ispinesib was conferred by the D130A 
mutation as predicted, the L214A expressing cells remained highly sensitive to it. Using 
molecular dynamics simulations, we identify that a subtle difference in conformational 
flexibility between Arry-520 and ispinesib is responsible for the difference in inhibitory 
activity against the L214A mutant. We discuss the significance of these results with respect to 
differential binding to wild type and mutant states at the molecular level and the implications 
this has for emerging drug resistance when using drugs that target the allosteric-binding site 
of Eg5.  
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Materials and Methods 
Cell tissue culture 
U2OS cells were obtained from ATCC (ATCC® HTB96™) and were characterized and 
authenticated by ATCC and not by the authors using a comprehensive database of short 
tandem repeat DNA profiles.  The previously selected STLC resistant clones U2OS-
Eg5(D130A) and U2OS-Eg5(L214A) (28) were grown in D-MEM (Gibco BRL; Paisley, 
UK), supplemented with 10% fetal calf serum (Hyclone) in the absence or presence of 10 µM 
STLC (Novabiochem, Merck KGaA, Darmstadt, Germany). The cells were not tested for 
Mycoplasma. Before exposure to Arry-520 or ispinesib, cells were washed with STLC-free 
media three times for 5 min and then replaced with medium containing either 10 nM of Arry-
520 (TOCRIS Bioscience) or ispinesib (TOCRIS Bioscience).  
 
Immunofluorescence microscopy 
Cells were grown on poly-D-lysine (Sigma-Aldrich, Saint Louis Missouri)-coated 12-mm-
diameter glass coverslips and then exposed for 8 h to 10 µM STLC (from 50 mM stocks in 
DMSO), 10 nM Arry-520 or 10 nM ispinesib (from 10 PM stocks in DMSO) at 37°C. Cells 
were then fixed by incubation in 2% paraformaldehyde (20 min at 37 °C) and permeabilized 
with 0.2% Triton X-100 in PBS for 3 min before being incubated with primary and stained 
with secondary antibodies. MTs were detected by a mouse monoclonal anti-E-tubulin 
antibody (SIGMA) used at 400-fold dilution. The Alexa fluo-488 goat anti-mouse secondary 
antibodies (Invitrogen) were used at 400-fold dilution, respectively. DNA was detected with 
4',6-diamidino-2-phenylindole dihydrochloride (DAPI) with the VECTASHIELD (Vector 
Laboratories Inc, Burlingame, CA) mounting medium. 
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Images were collected with an inverted Olympus IX81 epifluorescence motorized microscope 
equipped with a motorized piezo stage (Ludl Electronic Products, USA) and a sCMOS 
(Hamamtsu Orca Flash4) camera driven by VOLOCITY software (Improvision Ltd, UK) with 
a binning of 1, using a PlanApo 60x NA1.42 objective (Olympus). Images were processed in 
Adobe Photoshop CS5 (Adobe) and assembled in Adobe Illustrator (Adobe). Mitotic cells 
were scored based on their phenotypes in triplicates, as either bipolar or monoastral. 
 
Flow Cytometric Analysis 
Cells were first fixed and labeled with propidium iodide as described previously. Data were 
collected with a MACSQuand instrument (Miltenyi Biotec, Germany). For each sample 
10,000 events were collected and aggregated cells were gated out. 
 
Crystal violet colony staining of U2OS STLC resistant clones 
Cells (2k cells/ plate) were plated in 6-well plates and the day after seeding, cells were treated 
with the inhibitors. The media was changed every four days and on day 10, when colonies 
started appearing visible cells were washed twice with ice cold PBS and fixed with 100% ice 
cold methanol for 10 min. Then the cells were stained with 0.5% crystal violet in 25% ice 
cold methanol for additional 10 min. Following excessive washes with double distilled water 
the plates were dried at room temperature and then images were taken using a scanner. For 
quantification of crystal violet staining, cells were plated at a density of 17,000 cells per well 
on a 24-well plate and subjected to the indicated concentrations of inhibitors. After 4 days, 
cells were washed with PBS, fixed with 4% paraformaldehyde for 20 min, stained with 0.5% 
crystal violet (C3386, Sigma-Aldrich) for 30 min, rinsed with deionized water, and air dried. 
Crystal violet solution was then solubilized using 10% acetic acid for 20 min, diluted 1:4 with 
deionized water and the absorbance (595 nm) was read using an Eppendorf Biophotometer.  
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Live cell imaging 
Cells were grown in 2-well Labtek chambers and just before recording, the medium was 
changed to DMEM/F-12, HEPES, without phenol red, supplemented with 10% fetal bovine 
serum and either 10 PM STLC, 10 nM Arry-520 or 10 nM Ispinesib. Cells were recorded 
with an inverted Olympus IX81 microscope with a DIC 20x objective (1 NA) binning of 1 
equipped with an environmental control chamber using a sCMOS (Hamamtsu Orca Flash4) 
camera driven by VOLOCITY software. Images were acquired at 3 min intervals. For 
analysis, at least 100 cells were followed for 16 h and for each condition the time of each cell 
spent in mitosis was recorded. The duration of mitosis for each cell was measured from the 
first time point that an interphase cell started to contract before becoming circular until the 
end of cytokinesis when the two daughter cells started to spread. Cells undergoing normal 
cytokinesis were scored as normal mitosis whereas cells that did not undergo cytokinesis and 
remained circular were scored as blocked in mitosis. Cells undergoing cytokinesis of tripolar 
spindles, slippage or death were scored as aberrant mitotic exits.  
 
Expression and purification of human Eg5 
Cloning, expression and purification of the motor domain of Eg5 (residues 1–368) was 
performed as described previously (Kaan et al., 2010)(34).  
 
Isothermal titration calorimetry (ITC) experiments 
ITC experiments were performed as previously described in Talapatra et al, 2013 (31) with 
minor modifications. Eg5 was used at a concentration of 12.5 μM for the ITC experiments. 
Inhibitors were diluted to an appropriate concentration in ITC buffer (50 mM HEPES pH 6.8, 
200 mM NaCl, 0.5 mM ADP and 2 mM MgCl2) so that the final solution contained no more 
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than 1% DMSO. To maintain a similar buffer composition for titrations, 1% DMSO was 
added to the protein solution. Arry-520 was used at a concentration of 100 μM. There were no 
detectable solubility issues at these concentrations. ITC experiments were performed with a 
MicroCal PEAQ-ITC (Malvern Instruments, UK) instrument. Titrations were carried out at 
25°C with a stirring speed of around 750 rpm. In total, 30 injections were performed for one 
protein inhibitor experiment with the first injection of 0.3 μL followed by 29 injections of 1.3 
μL and a gap of 120 s between each injection. Data analyses were performed after subtraction 
of the heats of dilution obtained from titration of Arry-520 into ITC buffer. The 
thermodynamic parameters N (stoichiometry), Kd (dissociation constant/binding affinity), ΔS 
(entropy change) and ΔH (enthalpy change) were obtained by using the single-site-binding 
model of the PEAQ-ITC analysis software (Malvern Instruments, UK). For each experiment, 
at least two titrations were performed. Titration data were analysed independently, and the 
means of obtained values reported. 
 
Crystallisation, structure determination and refinement of Eg5-Arry-520 complexes 
Eg5 at 10 mg/ml was incubated with 2 mM of Arry-520 for 2 h at 4qC before crystallisation 
trails. Initial crystals of the complex in space-group P212121 were obtained after one week at 4 
qC on mixing 1 Pl of the Eg5 complex with 1 Pl of either condition 1 (0.1 M MES pH 5.5, 
25.5% PEG 3350 and 0.25 M (NH4)2SO4) or condition 2 (0.1 M HEPES pH 6.5, 0.2 M 
K2HPO4 and 33% PEG 3350) buffer by vapor diffusion in sitting drops. Crystals in space-
group P32 appeared in 0.04 M KH2PO4 and 12.5% PEG 8000 after 3 days. For data collection, 
diffraction quality single crystals were cryo-protected using 1.2x the concentration of the well 
solution and 15% (v/v) glycerol. The crystals were then flash frozen in liquid nitrogen for 
subsequent measurements using synchrotron radiation.  
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Diffraction data were collected at beamline I03 and 104-1 at Diamond Light Source. Data 
were processed and scaled using either iMosflm or XDS (35) and truncated using SCALA 
from the CCP4 suite of programs (36). The structures of the Eg5-Arry-520 complexes were 
solved by molecular replacement (PHASER MR in CCP4 suite) using the native Eg5-
monastrol structure (PDB code 1X88, (37) as a search model. All structures were initially 
refined with REFMAC5 (38). Electron density and difference density maps, all σA-weighted, 
were inspected, and the models were improved using Coot (39). The refinement of the 
structure was performed using PHENIX. The calculation of Rfree used 5% of data. 
Crystallographic and refinement statistics are given in Supplementary Data Table S1.  
 
In both structures, several regions are flexible and not visible in the electron density. In space 
group P212121 with two molecules in the AU, molecule A covers residues Lys17 to Asn29, 
His38 to Thr249, Leu255 to Asn271 and Asn287 to Val365. In molecule B, the following 
residues are visible: Lys17 to Ala31, His38 to Gly56, Ser61 to Asn271 and Asn287 to 
Glu364. Space group P32 contains three molecules in the AU and comprises the following 
residues. Molecule A: Ala16 to Glu247, Glu254 to Asn271 and Asn287 to Glu364. Molecule 
B: Lys17 to Lys246, Leu255 to Asn271 and Asn287 to Glu364. Molecule C: Lys17 to 
Asn271, Asn287 to Leu302 and Val309 to Pro363.     
 
Molecular Dynamics Simulations 
The crystal structure of Eg5 in complex with ispinesib (PDB ID 4A5Y) and SB743921 (PDB 
ID 4AS7) were downloaded from the protein data bank (www.rscb.org). The 4AS7 structure, 
which has complete loops for residues 30-37 and 272-286, was used as a template to model 
the missing loops in the Eg5-Arry-520 complex described in this study. Additionally, the 
4AS7 structure is an A133D mutant with a cadmium ion. The side chain of Asp133 in loop L5 
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was replaced with Ala at position 133 without any change in the backbone conformation 
using the ICM-Pro software (www.molsoft.com) and cadmium was mutated to magnesium. 
The structural analog SB743921 in 4AS7 was replaced with ispinesib by superimposition of 
the two structures and retaining the coordinates of ispinesib. The Eg5(L214A) mutant in α3 
helix was generated by replacing the side chain of Leu with Ala in the modeled Eg5 structure. 
The backbone root mean square deviation calculated over 347 residues between the 
Eg5(L214A)-ispinesib and the Eg5(L214A)-Arry520 complex is 0.36 Å and that between 
Eg5(D130A)-ispinesib and the Eg5(D130A)-Arry520 complex is 0.12 Å. Parameters for the 
ligands were generated using antechamber software (40) after geometry optimization at the 
B3LYP/6-31G(d) level and RESP charge fitting (41) using electrostatic potential obtained at 
the HF/6-31G(d) level. The parameters of ADP were adapted from Meagher et al(42). The 
complexes were set up using xleap employing the ff14sb forcefield (43) for the protein and 
GAFF2 for the ligands. The complexes were solvated using TIP3P water (44) and the edge of 
the box was set to at least 10 Å from the closest solute atom. The system was neutralized with 
K+ and Cl- ions. The protocol was identical for all systems. Each system was minimized and 
relaxed under NPT conditions for 5 ns at 1 atm. The temperature was ramped up to 298K 
using a timestep of 4 fs, rigid bonds, a cut-off of 9 Å and a particle mesh Ewald summations 
switched on for long-range electrostatics. Only the solvent and ions were allowed to move 
during the equilibration. The heavy atoms of the protein and ligands atoms were constrained 
by a spring constant set at 1 kcal/mol/Å2. The production simulations were run using ACEMD 
(45) molecular dynamics engine in the NVT ensemble using a Langevin thermostat with a 
damping of 0.1 ps -1 and hydrogen mass repartitioning scheme to achieve time steps of 4 fs 
(46). The final production step was run without any constraints for 555 ns. The analysis was 
carried out using the final 255 ns of simulation time. Visualization of the simulation was done 
using ICM-pro Molsoft and VMD package (47). 
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Results 
Determination of the binding affinity of Arry-520 for Eg5 by isothermal titration calorimetry 
(ITC) 
The IC50 of Arry-520 against Eg5 has previously been reported as low nanomolar using a 
kinetic ATPase activity assay (48). To measure the binding affinity of Arry-520 for Eg5, we 
employed a biophysical assay using our well-established ITC protocol for high affinity 
inhibitors (12), which  showed that Arry-520 is a tight-binding inhibitor with a Kd value of ~ 
460 pM (Figure 1b) in the absence of MTs. Thermodynamic parameter extraction from the 
ITC experiments indicated a profile similar to our previous analysis of the ispinesib analogue 
SB743921 with wild-type Eg5. Like SB743921, binding between Arry-520 and Eg5 is 
primarily driven by an enthalpic contribution, although there is a small positive entropic 
contribution rather than a penalty with this ligand.  Data analysis indicated that the binding 
data fit well to a single binding site model with a stoichiometry close to unity, signifying a 1:1 
complex with the Eg5 motor domain similar to most other loop L5 binding agents and 
suggesting that Eg5-Arry-520 co-crystallization was likely to succeed.  
 
Overall description of two Eg5-Arry-520 complexes in two distinct space groups 
Two structures of the Eg5-Arry-520 complex in two different space groups were solved at 2.8 
Å and 2.75 Å resolution and were refined to Rfree values of 27.1% and 25.2%, respectively. 
Data processing and refinement statistics are shown in Supplementary Data Table S1.  
Crystals in space group P212121 contain two molecules of Eg5 in the asymmetric unit (AU), 
each bound with Arry-520, whereas those obtained in space group P32 contain three 
complexes in the AU. All five motor domain structures fit to the canonical kinesin motor 
domain fold with an eight-stranded E-sheet sandwiched between three major D-helices on 
each side (Figure 1c). Each motor domain has one molecule of Mg2+ADP bound in the 
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nucleotide-binding pocket. In all five motor domain structures, Arry-520 occupies the 
conventional allosteric inhibitor-binding pocket formed by helix α2, loop L5 and helix α3 
(Figure 1d). In the Eg5-Arry-520 complexes, the loop L5 region is ordered and visible (Figure 
1d) unlike in the unbound structure of Eg5, where this region is mostly disordered and absent 
(49). 
 
Eg5-Arry-520 complexes in the intermediate and final inhibitor bound state 
Comparison of the five Eg5-Arry-520 complexes from two distinct space groups with the 
native unbound Eg5 structure (PDB entry 1II6; (49))  reveals major structural changes in the 
switch II cluster (helix α4/loop loop L12 and helix α5) and the so-called neck-linker region 
(Supplementary Figure S1). The binding of Arry-520 to the loop L5 region induces 
conformational changes in and around the inhibitor-binding pocket (switch I), which are 
transmitted to the switch II cluster and the neck-linker region following helix α6. Both 
intermediate and final inhibitor bound states are evident in our structures: in space group P32, 
one of the three molecules in the AU (molecule C) is in the intermediate bound state, where 
the switch II cluster is in the obstructive conformation forcing the neck linker region to be 
perpendicular to the motor domain (Supplementary Figure S1b).  In contrast, the other 
complexes in space groups P212121 and P32 are in the “final” inhibitor bound state. In this 
conformation, the switch II cluster is in the permissive conformation, which enables the neck-
linker to dock to the motor domain (Supplementary Figure S1b). These conformational states 
have previously been observed in Eg5 complexes with STLC (34) and ispinesib (33),(50) and 
strongly suggest that Arry-520, by binding to the L5 allosteric inhibitor pocket, invokes a very 
similar structural mechanism to other Eg5 inhibitors. 
 
Detailed molecular interactions between Eg5 and Arry-520 
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In all five Eg5-Arry-520 complexes the inhibitor is buried in the allosteric inhibitor-binding 
pocket. Overall, the binding conformations and interactions of Arry-520 with residues in the 
inhibitor-binding pocket in all complexes are very similar (Figure 1e & Supplementary Figure 
S1c). The 2-phenyl group is oriented towards the protein interior and engages in hydrophobic 
interactions with a range of side chains including Trp127, Pro137 (both T-face edge-to-face 
stacking aromatic interactions), a π-cation interaction with the guanidine group of Arg119 and 
a hydrophobic interaction with the propyl region of its side chain and with the methyl group 
of Ala133. Several main chain carbonyl oxygen atoms are also in close vicinity to the 2-
phenyl group. The 2,5-difluorophenyl substituent is also buried in the inhibitor-binding 
pocket and is sandwiched between the side chains of the conserved Glu116-Arg221-Glu162 
ion pair (forming a π-cation interaction with the guanidine group of Arg 221) and Leu214, 
and is surrounded by a variety of other hydrophobic side chains (Ile136, Phe239 and Leu160). 
Although the 1,3,4-thiadiazole ring does not display short range interactions with residues of 
the binding pocket, its geometry facilitates the optimal positioning of its four substituents with 
different regions of the binding site. We observe subtle conformational flexibilities within the 
solvent-orientated methoxy group of the N-methoxy-N-methyl substituent and the primary 
propylamine moiety. The position/conformation of the primary amine oscillates slightly and 
forms hydrogen bond interactions with the side chain of Glu116 (2.7 Å - 4.1 Å) and the main 
chain carbonyl oxygen of Gly117 (2.9 Å - 3.7 Å) simultaneously, whilst the side chain of 
Glu118 appears to be too far away (5.7 Å – 6.4 Å) to form any effective hydrogen bond 
interactions. We also observe variation in the conformation of the N-methoxy substituent, 
which forms a hydrogen bond interaction between its oxygen and the side chain hydroxyl of 
Tyr211 (2.7 Å - 3.1 Å). The methyl groups of this N-methoxy-N-methyl substituent form 
hydrophobic interactions with the side chains of Ala218 and the hydrophobic ethyl region of 
the Glu215 side chain.  
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The structure of the Eg5-Arry-520 complex demonstrates that Arry-520 binds to the same 
allosteric pocket as other Eg5 loop L5 binding inhibitors and interacts with a number of 
common residues within this site (33). This therefore raised the question as to whether known 
mutations in the allosteric pocket responsible for conferring resistance to inhibitors such as 
STLC (30) and monastrol (5) could also induce cellular resistance to Arry-520. To answer 
this question, we assessed Arry-520 against two clones of U2OS tumor cells selected for 
growth in the presence of STLC through the expression of mutant alleles of Eg5 for each of 
the D130A or L214A residues (28), and compared the phenotypes with the clinically 
evaluated inhibitor ispinesib (SB-715992; multiple phase I and II trials) (51).  
 
Cell cycle progression of U2OS cells expressing either Eg5(D130A) or Eg5(L214A) STLC 
resistant clones in the presence of Arry-520 or ispinesib 
The impact on cell cycle progression after 24 h exposure to the three Eg5 inhibitors was first 
studied by flow cytometric analysis (Figure 2a). Naïve U2OS cells exposed to either STLC, 
Arry-520 or ispinesib were blocked at the G2/M stage with 4N DNA content. In contrast to 
the naïve cells, Eg5(D130A) and Eg5(L214A) expressing cells were cycling normally both in 
the absence and presence of either STLC or Arry-520. However, in the presence of ispinesib, 
only the Eg5(D130A) expressing cells showed normal cell cycle profiles. Eg5(L214A) 
expressing cells, although fully resistant to either STLC or Arry-520, were still highly 
sensitive to ispinesib, as they accumulated in G2/M. 
 
Spindle formation in naive U2OS cells and in STLC resistant clones of U2OS expressing 
either Eg5(D130A) or Eg5(L214A) in the presence of Arry-520 or ispinesib 
 17 
The cell cycle profile of both STLC-resistant cell lines indicated that the cells were able to 
divide normally in the presence of Arry-520. To confirm the presence of normal bipolar 
spindles in these cells exposed to Arry-520 and in order to identify the phenotype of the 
Eg5(L214A) expressing cells blocked in G2/M in the presence of ispinesib, we carried out 
indirect immunofluorescence microscopy. Naïve U2OS cells and cells from the Eg5(D130A) 
and Eg5(L214A) U2OS clones were exposed to either STLC, Arry-520 or ispinesib. As 
expected, all three inhibitors induced monoastral spindles in the naïve cells due to the 
inhibition of Eg5 activity: MTs were nucleated from the duplicated but not-separated 
centrosomes extending into the cytoplasm in a monoaster configuration while chromosomes 
were distributed along the MT in a centripetal fashion (Figure 2b). The vast majority of the 
spindles (close to 100%) were monoastral (Figure 2c). In contrast to the naïve U2OS cells, 
cells expressing the Eg5(D130A) mutant allele were capable of forming normal bipolar 
spindles in the presence of all three inhibitors and proceeded normally to anaphase. At 
concentrations at which all three inhibitors produce 100% inhibition in the naïve cells, only 
20% of the spindles were monoastral in the presence of STLC and Arry-520 and 47% in the 
presence of ispinesib in the Eg5(D130A) expressing cells. A more striking difference was 
observed in cells expressing the Eg5(L214A) mutant allele: only 19% and 11% were 
monoastral in the presence of STLC or Arry-520, respectively, indicating no sensitivity to 
these inhibitors, whereas the vast majority of the spindles in this mutant were monoastral 
(99%) when exposed to ispinesib, indicative of high sensitivity (Figure 2b). 
 
Duration of mitosis in naïve U2OS and in Eg5(D130A) or Eg5(L214A) expressing cells in the 
presence of allosteric Eg5 inhibitors 
The ability of the two STLC-resistant U2OS clones to undergo regular cell division following 
normal bipolar spindles formation and enter into anaphase in the presence of the three 
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inhibitors was further examined by time-lapse imaging (Supporting Videos SV1-6).  The time 
spent in mitosis for more than 100 cells from all three cell lines in the presence of the 
inhibitors was measured and compared to that of the untreated cells (Figure 3). Cells 
undergoing standard mitosis resulting in normal cytokinesis were scored as normal M. Cells 
that underwent tripolar anaphase resulting in three daughter cells or underwent aberrant 
mitotic exit without cytokinesis or entered death, were scored as aberrant M exit. Cells that 
entered mitosis as judged by their morphological changes from the spread interphase 
configuration to a round shape (and remaining so) throughout the period of observation were 
scored as arrested in M (Table 1).  
 
The vast majority (94.8%) of the untreated naïve U2OS cells completed mitosis normally. 
90.1% of the mitotic cells completed mitosis in less than 1 h, with 97.2% completion achieved 
in less than 2 h (Tables 1 and 2). In contrast, only 1.3% of the naïve U2OS cells completed 
mitosis successfully following treatment with Arry-520. As expected from our previous 
observations (28), the majority of the mitotic cells expressing either Eg5(D130A) or 
Eg5(L214A) completed mitosis in the presence of STLC normally (89.8% and 94.5%, 
respectively). As with the naïve cells, the majority of these cells completed mitosis within 1 h 
and almost all of them within 2 h (Table 2). When treated with Arry-520, both the 
Eg5(D130A) and Eg5(L214A) expressing cells were capable of completing normal mitosis, 
reaching 51.4% and 91.8%, respectively, although the former cell line experienced longer 
mitotic delays; 51.8% of the mitotic cells completed mitosis within 1 h and 67.7% in less than 
2 h (Figure 3). The Eg5(L214A) expressing cells passed through mitosis within similar 
duration as the naïve untreated U2OS. In the presence of ispinesib, the Eg5(D130A) 
expressing cells divided normally without experiencing any notable mitotic delays, whereas 
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the Eg5(L214A) cells were blocked in mitosis (84.6%) and displayed monoastral spindles 
(Figure 2b & c).  
 
Colony formation of U2OS cells expressing either Eg5(D130A) or Eg5(L214A) STLC 
resistant clones in the continuous presence of Arry-520 or ispinesib.   
The differential sensitivity of the cells to the antiproliferative effect of the inhibitors was 
investigated by assessing colony formation after prolonged exposure (10 days) (Figure 3b). 
Colonies were readily visible in all three untreated cell lines; naïve cells treated with STLC, 
Arry-520 or ispinesib were incapable of proliferation and did not form colonies. Eg5(D130A) 
expressing cells showed resistance to the antiproliferative effects by readily forming colonies 
in the presence of the three inhibitors. In contrast, Eg5(L214A) expressing cells were capable 
of colony formation in the presence of both STLC and Arry-520, but not in the presence of 
ispinesib, indicating their susceptibility to the antiproliferative effects of the latter only. 
Quantification of crystal violet staining of treated cells confirmed the marked lack of viability 
of Eg5(L214A) expressing cells exposed to ispinesib (Figure 3c and d) compared to similarly 
treated Eg5(D130A) expressing cells. 
 
Taken together, our cell-based assays indicate that mutations in the loop 5 allosteric binding 
pocket that confer resistance to inhibitors such as STLC and monastrol also affect Arry-520. 
In the case of ispinesib, although resistance occurred in the Eg5(D130A) expressing cells, the 
Eg5(L214A) cell line was highly sensitive to its antimitotic effects, suggesting that the L214A 
mutation does not adversely impact the inhibitory mechanism that this particular scaffold has 
on Eg5. 
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Molecular dynamics simulations of Eg5 and Eg5(L214A) in complex with Arry-520 and 
ispinesib.   
In order to explore the subtle differences between the binding of inhibitors to the allosteric 
site in the Eg5 wild type and mutant complexes, we carried out conformational sampling via 
molecular dynamics simulations. Eg5 has previously been co-crystallized with ispinesib (PDB 
ID 4A5Y) and a related analogue SB743921 (PDB ID 4AS7), which both occupy the 
allosteric site in an orientation similar to the one described for Arry-520 in this study 
(Supplementary Figure S2). The quinazolin-4-one ring of ispinesib occupies an internal 
hydrophobic pocket that is sandwiched between the Glu116-Arg221 ion-pair (Supplementary 
Figure S2d) and the aliphatic side chain of Leu214 in the wild type complex. The rest of the 
scaffold makes non-bonded interactions around the predominantly hydrophobic binding site 
(Supplementary Figure S2b). The difluorophenyl ring of Arry-520 is sandwiched in a similar 
way to the quinazolinone ring of ispinesib in the wild type structure (Supplementary Figure 
S2a and c). From these structures, the mutant complexes were generated by replacing the Leu 
or Asp side chains with Ala. The ΔΔG of the Leu to Ala change was 0.22 kcal/mol and results 
in an enlargement of the binding pocket from 297 Å3 to 306 Å3. For the Asp to Ala change, 
the ΔΔG of was 0.68 kcal/mol and changes the binding pocket volume from 395 Å3 to 404 
Å3. The complexes were then subjected to molecular dynamics simulations to extract changes 
in the flexibility of Arry-520 and ispinesib due to structural perturbations induced in the 
allosteric binding site as a consequence of either the L214A or D130A mutation (Figure 4a-c’ 
and Supporting videos SV7-SV12). Four simulations were run for 555 ns each and all 
analyses carried out on the equilibrated trajectory, which included the final 250 ns of 
simulation time. The difluorophenyl ring of Arry-520 is sandwiched in a similar way to the 
quinazolinone ring of ispinesib in the wild type structure. The hydrogen bond interactions 
formed between the primary amine of Glu117 and the N-methoxy groups and the binding site 
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are stable and maintained throughout the course of the simulation (Supplementary Figure S3). 
The dihedral angle between the 2,5-difluorophenyl and the 1,3,4-thiadiazole ring in Arry-520 
was monitored in all complexes, along with the dihedral angle between the quinazolin-4-one 
ring and the isopropyl group in ispinesib (Figure 4d & e). In the Eg5(L214A)-mutant 
complex, ispinesib displays similar interactions and dynamics to that observed in the wild 
type, which could explain why both are sensitive to inhibition by this molecule. There is little 
conformational flexibility in the ligand, as exemplified by the rotation of the isopropyl group 
with respect to the quinazolinone ring oscillating tightly around 70o (Figure 4f). The behavior 
of Arry-520 in the wild type and L214A complexes is different. In the former, Arry-520 is 
tightly anchored in the allosteric binding site by hydrogen bonding interactions and the 
difluorophenyl group is tightly sandwiched between conserved Glu116-Arg221-Glu162 and 
Leu214 side chains. There is little conformational flexibility displayed by the inhibitor 
throughout the simulation, suggesting a tight-binding mode. The small entropic contribution 
(T'S = 2.87 kcal/mol) to the binding free energy ('G -12.43 kcal/mol) as determined by ITC 
supports the low conformational flexibility seen in this simulation. In the Eg5(L214A)-
mutant, the primary amine hydrogen bonds with the Glu116 side chain and the Gly117 
backbone carbonyl oxygen, similar to that in the wild type (Supplementary Figure S3). 
However, at ~460 ns, the side chain of Tyr211 rotates away from the site resulting in the loss 
of the hydrogen bond between the N-methoxy oxygen and the hydroxyl group of Tyr211 and 
greater movement between the two moieties (Supplementary Figure S3d). Arry-520 remains 
tethered in the allosteric binding site via the hydrogen bond interactions made through the 
primary amine (Supplementary Figure S3). However, the larger volume of the binding pocket 
generated as a result of the L214A mutation and the rotation of Tyr211 loosens Arry-520 
packing in the internal hydrophobic pocket. This results in enhanced wobbling of the 
diflurophenyl substituent (Figure 4f upper panel). The difference in flexibility between the 
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tight-binding in the wild type, and the more flexible conformation in the Eg5(L214A) 
complex could be responsible for the induction of resistance to Arry-520 in this mutant, in 
stark contrast to ispinesib. 
  
Analysis of the D130A complex trajectories with ispinesib revealed that the bond angle 
between the quinazolinone ring and the isopropyl group is stabilized at a different angle 
(~130o) than observed in wild type Eg5 or Eg5(L214A) (Figures 4b’, 5f lower panel), which 
is due to the conformation adopted by loop 116-135 in the D130A mutant. An ion-pair 
interaction is formed between Arg119 and Glu125, which is very stable when ispinesib is 
present. The Arg119 side chain is also positioned perfectly to form a hydrogen-bond 
interaction simultaneously with the exocyclic amide oxygen of ispinesib, thus restricting 
rotation around the quinazolinone-isopropyl bond to a different angle than observed in the 
other ispinesib complexes sensitive to inhibition (Figure 4a’-c’, 4f lower panel). We also 
observed an increase in the flexibility of loop L5 (residues 116 to 135) compared to wild type 
Eg5 and L214A complexes despite the Arg119-Glu125 tether (Supplementary Figure S3e). 
This suggests that enhanced flexibility in this region coupled with a different conformation of 
ligand binding could be responsible for the resistance to ispinesib observed with the D130A 
mutant. 
In this region, the behavior of Arry-520 is similar in all three complexes, suggesting that these 
specific local interactions are not responsible for wild type sensitivity or mutation-induced 
resistances to this scaffold. Arg119 does not form any direct stable interactions with Arry-520 
and no Arg119-Glu125 ion-pair interactions within the protein are evident. 
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Discussion 
The first two crystal structures of the Eg5-Arry-520 complex convincingly show that Arry-
520 is buried in the same conventional inhibitor-binding pocket (D2 / loop L5 / helix D3) as 
observed for allosteric inhibitors such as ispinesib, STLC and others. Overall, the tight 
binding of Arry-520 is achieved through a number of strong and weak hydrogen bond 
interactions as well as hydrophobic interactions with the side chains of amino acids lining the 
inhibitor-binding pocket. We compared the structure of the Eg5-Arry-520 complex with that 
of the Eg5-ispinesib complex (PDB ID: 4AP0), (33) (Figure 1f). Superimposition of the two 
complexes showed that the quinazolinone of ispinesib occupied a similar position to the 
difluorophenyl ring of Arry-520, with similar interactions such as the chlorine mimicking one 
of the polar fluorine interactions with Tyr211. An interesting difference between each ligand 
involves the p-toluyl and benzyl groups of ispinesib and the benzyl moiety of Arry-520. In 
ispinesib, these two aromatic substituents stack with each other, which stabilizes a further 
stacking interaction with the backbone of Glu118, Arg119 and the side chains of Arg119, 
Trp127 and Asp130. This backbone stacking interaction is much weaker in the Eg5-Arry-520 
complex. A second difference involves the hydrophobic interaction with Leu214. With Arry-
520, there is a direct hydrophobic stacking interaction between the difluorophenyl group and 
the isobutyl side chain of the residue, whereas in the ispinesib complex, the side chain has 
shifted by 2 Å to accommodate the benzyl and p-toluyl groups thereby weakening or losing 
this interaction altogether. Arry-520 and ispinesib form hydrogen bond interactions between 
the primary amine and the main chain oxygen of Gly117 and the side chain of Glu116. The 
oxygen of the methoxy group in Arry-520 may form a weak hydrogen bond interaction with 
the hydroxyl group of Tyr211 (3.63 Å). Furthermore, one fluorine in the phenyl ring interacts 
with the main chain NH of Gly217 (3.03 Å) and also weakly with the side chain of Arg221 
(3.69 Å).  The crystal structure of Eg5 complexed with a 1,3,4-thiadiazole core scaffold has 
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recently been published (Supplementary Figure S1e) (52). K858 represents a smaller, pre-
optimised version of Arry-520 that lacks the key substituents necessary for potent inhibition.  
 
The  D2 / loop L5 / helix D3 pocket has been the focus of a number of mutagenesis studies in 
order to understand not only the mode of interaction of Eg5 with its various inhibitors but also 
how the ligands exert their allosteric inhibition (26),(10). We have previously shown that 
mutations in this binding pocket can confer resistance in cells to inhibitors that are known to 
bind to this pocket, such as monastrol and STLC (29). Notably, we have previously used the 
expression of the two point mutations D130A and L214A in the Eg5 binding pocket to 
discriminate loop L5 binding inhibitors from those capable of interacting with other binding 
sites such as the ATP competitive inhibitors (28).  We have shown here that these two STLC 
resistant cell lines, one harboring and expressing D130A and the other L214A in Eg5, are also 
resistant to Arry-520 treatment, since the majority of the cells from both cell lines were able 
to form normal bipolar spindles (Figure 2). Live cell imaging showed that STLC-resistant cell 
lines treated with Arry-520 did not experience delays in passing through mitosis and divided 
normally (Figure 3). Flow cytometric analysis showed normal cell cycle profiles for STLC-
resistant cells in common with control naïve untreated cells (Figure 2). Finally, exposure to 
Arry-520 did not inhibit the ability of both STLC-resistant cell lines to form colonies after 
long exposure. Based on these results, we can conclude that both D130A and L214A 
mutations in the Eg5 allosteric binding site can confer similar resistance to Arry-520, as they 
do with STLC. Moreover, they also suggest that the primary, if not the only mitotic target of 
Arry-520, is indeed Eg5.  
 
An unexpected outcome emerged when comparing the inhibitory activities of the two 
clinically advanced inhibitors Arry-520 to ispinesib in STLC-resistant cell lines. Both Arry-
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520 and ispinesib were ineffective in the Eg5(D130A) expressing STLC-resistant cells, which 
was to be expected since the D130V allele of Eg5 was previously identified as conferring 
resistance to ispinesib and its closely related analogue SB743921 (31). However, a 
significantly different sensitivity to the two inhibitors was seen in the Eg5(L214A) cell line. 
Although Arry-520 was ineffective in Eg5(L214A) expressing cells in common with STLC 
and other loop L5 binding inhibitors, ispinesib was still fully capable of inhibiting growth. 
Monoastral spindle development was evident, cells were blocked in mitosis without 
proceeding to anaphase (Figure 2) and failed to form colonies after prolonged exposure to 
ispinesib (Figure 4). 
 
This differential resistance of the Eg5(L214A) expressing cells to Arry-520 and ispinesib 
appears to challenge our previous proposition of using these two resistant cell lines as tools in 
phenotype based screening to determine if other novel Eg5 inhibitors bind to the conventional 
allosteric site of Eg5 without any previous structural information (28). From a structural 
perspective based on a crystallographic snapshot, this is difficult to rationalize. Leu214 is 
involved in a network of hydrophobic interactions with the side chains of Ile136, Pro137, 
Val210 and Phe239 within the allosteric inhibitor-binding cavity and both ispinesib and Arry-
520 bind in a similar orientation within this site. The diflurophenyl and the quinazolinone 
rings are tightly sandwiched between the conserved ion-pair interactions of Glu116-Arg221-
Glu162 and the hydrophobic stacking interactions of Leu214, despite its side chain having 
shifted by 2 Å to accommodate the benzyl and p-toluyl groups of ispinesib.  
 
Analysis of the simulated dynamic trajectories of wild type and mutant complexes rather than 
relying on static structures offers possible explanations for these differences in sensitivity. In 
ispinesib, the quinazolinone ring has two substituents (isopropyl and benzyl), each connected 
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to it by a rotatable bond. During the simulations, the rotation around these bonds is restricted 
in wild type Eg5 by the tight packing of the isopropyl group against the backbone of Leu214 
in helix-D3 and the benzyl ring to the side chain of Leu214 (Figure 4). This places ispinesib in 
a highly constrained and favorable hydrophobic chemical environment, inferring a tight-
binding complex that results in effective inhibition. In the Eg5(L214A)-ispinesib mutant 
complex, despite the removal of the Leu side chain, the increase in volume is not enough to 
allow greater overall substituent flexibility in the ligand (Figure 4), as exemplified by the 
restriction of the rotational angle around the isopropyl-quinazolinone bond to the same degree 
and magnitude as the wild type (Figure 4). Overall, this resulted in a very similar dynamic and 
interaction profile around the allosteric binding site for both complexes, suggesting tight 
ligand binding and effective inhibition, which corresponds with the phenotypic outputs from 
the cell-based experiments conducted with ispinesib. Molecular dynamics simulations of the 
Eg5(D130A) bound to ispinesib revealed that the bond angle between the quinazolinone ring 
and the isopropyl group is stabilized at a different angle (Figure 4f), which is due to the 
conformation adopted by loop L5 and the consequent   hydrogen bond interaction between 
Arg119 and ispinesib. The additional increase in the flexibility of loop L5 compared to the 
wild type and L214A complexes allows greater conformational freedom within the ligand 
(Figure 4) thus reducing its tight-binding nature and compromising its ability to inhibit the 
mutated protein. We have previously shown that the reduced inhibition by the ispinesib 
analogue SB743921 in the D130V mutant (31) is also due to increased flexibility in this 
region: the loss of the side chain interaction between Asp130 and the side chains of Ser120 
and Arg119 and the main-chain amino groups of Ser120 and Leu132 reduce the structural 
stability of loop L5. A D130A mutation would compromise this same interaction network, 
which was reproduced by the higher flexibility of loop L5 in the D130A-ispinesib trajectory 
reported here. 
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In the simulated wild-type Eg5-Arry520 complex, hydrogen bonding interactions between the 
primary propylamino group and Glu116/Gly117 at one end of the ligand and the N-methoxy 
oxygen with the hydroxyl side chain of Tyr211 at the other locks Arry-520 in the allosteric 
binding site to produce a trajectory with restricted conformational flexibility (Figure 4). 
Unlike ispinesib, in the Eg5(L214A)-Arry520 mutant, the extra volume in the inhibitor 
binding pocket generated in the L214A mutation allows greater ligand flexibility, displayed 
by increased wobbling of the difluorophenyl group around the bond connecting it to the 
thiadiazole ring (Figures 4f). This appears to be linked with the increased distance between 
the N-methoxy oxygen and Tyr211 induced by the rotation of the amino acid side chain to 
weaken the hydrogen bond. The enhanced flexibility observed for Arry-520 would 
compromise its effectiveness as a tight-binding inhibitor, leading to resistance in cells 
containing this mutation. Comparison of the RMS fluctuation of the wild type and L214A 
loop 5 regions of the binding site also show greater plasticity in the latter (Supplementary 
Figure 3e), which is known to compromise allosteric transmission by inhibitors to the ATP 
binding site in resistant mutants (31). Notably, this region is less flexible in the L214A-
ispinesib complex, where inhibition is observed.        
 
To date, targeting Eg5 in cancer with small molecule inhibitors has had mixed outcomes 
clinically: despite a number of loop L5 binding agents entering clinical trials, results have 
been poor in solid tumors, whereas haematological cancers look to be more responsive (6). 
The reduced clinical efficacy of these inhibitors in solid tumors may be due to the low tumour 
cell proliferation rates and reduced drug penetration associated with these cancer types (16). 
The adverse reaction of neutropenia in clinical trials, a known consequence of Eg5 target 
engagement in normal cell proliferation (19), suggests that the efficacies and pharmacokinetic 
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profiles of the drugs under clinical investigation are not compatible with their narrow 
therapeutic indices in solid tumour scenarios.   The better pharmacokinetic profile of Arry-
520 and the associated reduced dosing frequency compared to other Eg5 inhibitors (53), 
combined with the high proliferation rate of relapsed multiple myeloma cells (14% to 83 %) 
(54) may be the reason for the better therapeutic index of Arry-520. Its totally different 
chemical scaffold may also have fewer off-target adverse effects than other Eg5 inhibitors, 
which may also contribute to a wider therapeutic index.   
Arry-520 has proved to be most effective in patients with relapsed or refractory multiple 
myeloma alone and in combination (17),(18), progressing to a phase III clinical trial and the 
possibility of becoming a valuable addition to the antimyeloma chemotherapeutic arsenal. Our 
studies here clearly show that Eg5 is the unique intracellular target for Arry-520 and thus 
offers an alternative way to target the cell cycle that differs from MT-targeting drugs currently 
used clinically to treat haematological cancers, such as vincristine.  
 
Multiple myeloma is caused by clonal expansion of malignant plasma cells within the bone 
marrow (55). Acquired genetic mutations within myeloma cells and their interaction with 
bone marrow stromal cells contribute to disease progression and drug resistance. Evidence 
emerging from the sequencing of patients with multiple myeloma has revealed an extensive 
clonal heterogeneity even within the same individual (56). A recent phenotypic screening 
study using co-cultures of multiple myeloma cells with bone marrow stromal cells led to the 
identification and characterization of a novel ATP non-competitive Eg5 inhibitor BRD9647 
that selectivity targeted myeloma cells over normal hematopoietic progenitors (13). 
Interestingly, a novel mutation in Eg5 at Y104C that is not located near the loop L5 allosteric 
binding site of other non-competitive inhibitors, caused resistance to BRD9647 suggesting it 
targets a distinct allosteric site. The current lack of clinical data associated with the long-term 
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use of Eg5 inhibitors in patients means information relating to acquired resistance will take 
time to emerge. It is therefore important to develop preclinical tools that can help predict the 
types and effects of mutations this class of compounds can generate during clinical evaluation 
and treatment, and understand the mechanisms at the molecular level that can lead to 
resistance. Our previous studies suggested that mutations in the L5 loop of Eg5 were scaffold 
independent (31), which had serious implications for drug design against this target. 
However, the sensitivity of the L214A mutant to ispinesib suggests that compounds can be 
engineered to avoid the reduced inhibition associated with some mutations that convey 
resistance across this class. Phenotypic screening employing the methods we describe here 
with a greater array of mutated cell lines, coupled with thermodynamic binding evaluations 
and structural and molecular dynamics studies should lead to a better understanding of the 
mechanisms that convey resistance at the target level, and enable the design of new inhibitors 
that can overcome these potentially clinically-relevant issues. Such inhibitors could then be 
used as suitable alternatives if acquired Eg5-related resistance to Arry-520 emerges during 
treatment, in a manner similar to the way that nilotinib succeeded imatinib when resistance 
was acquired during the treatment of patients with CML (57). 
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Table 1 Mitotic fate of individual naïve U2OS and Eg5(D130A) or Eg5(L214A) expressing 
U2OS cells in the presence of allosteric Eg5 inhibitors followed by time-lapse video. 
U2OS cells, 
treatment 
# M cells 
observed 
# M normal 
(% total) 
# M arrested 
(% total)  
# M exit aberrant 
(% total)  
Naïve 
untreated 192 94.8 0.5 4.7 
Naïve 
+ Arry-520 297 1.3 85.2 13.5 
Eg5(D130A) 
+ STLC 176 89.8 1.1 9.1 
Eg5(D130A) 
+ Arry-520 642 51.4 38.3 10.3 
Eg5(D130A) 
+ ispinesib 140 87.1 2.9 10.0 
Eg5(L214A) 
+ STLC 290 94.5 0.3 5.2 
Eg5(L214A) 
+ Arry-520 680 91.8 3.8 4.4 
Eg5(L214A) 
+ ispinesib 130 2.3 84.6 13.1 
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Table 2 Time which naïve, Eg5(D130A) or Eg5(L214A) expressing U2OS cells spent in mitosis, 
in the presence of allosteric Eg5 inhibitors, leading to successful cytokinesis. 
U2OS cells, 
treatment 
# cells that spent  
≤ 60 min in M 
(% of total M cells) 
# cells that spent 
 ≤ 120 min in M 
(% of total M cells) 
Naïve untreated 90.1 97.2 
Eg5(D130A) + STLC 89.2 100 
Eg5(D130A) + Arry-520 51.8 67.7 
Eg5(D130A) + ispinesib 79.5 95.1 
Eg5(L214A) + STLC 90.2 99.3 
Eg5(L214A) + Arry-520 84.7 94.9 
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Figure legends 
 
Figure 1. Structure of the Eg5-Arry-520 complex. a) Chemical structure of Arry-520. b) Raw 
data (top) and integrated data (bottom) from ITC measurements demonstrating high 
picomolar affinity and exothermic reaction upon sequential additions of Arry-520 to Eg5. c) 
Overall structure of the ternary Mg2+ADP–Eg5–Arry-520 complex showing the front view of 
the Eg5 motor domain with bound Mg2+ (red), ADP (green/orange) and Arry-520 (magenta). 
d) Magnification of the allosteric binding pocket of Eg5 (yellow) composed of helix α2, loop 
L5 and helix α3 with Arry-520 (magenta) and the electron density omit map (colored in blue) 
contoured at 3σ. e) Stereo plot of Arry-520 (magenta) and surrounding residues of the 
inhibitor binding pocket (colored in cyan). f) Comparison of the distinct binding modes of 
Arry-520 (magenta) and ispinesib (green); the protein surface is displayed semi-transparently.  
 
Figure 2. Cell cycle progression and spindle formation in naïve U2OS cells and cells  
expressing either Eg5(D130A) or Eg5(L214A) STLC resistant clones in the presence of Arry-
520 or ispinesib. a) Cell cycle distribution of cells after 24 h treatment with either 10 PM 
STLC, 10 nM Arry-520 or 10 nM ispinesib. Naive U2OS cell were blocked in 4N in the 
presence of either STLC, Arry-520 or ispinesib whereas U2OS cells expressing either 
Eg5(D130A) or Eg5(L214) were resistant to STLC and Arry-520 having normal cell cycle 
profiles as the untreated control cells. In stark contrast, U2OS cells expressing Eg5(L214A) 
cells were sensitive to ispinesib and they accumulated at 4N. b) Immunofluorescence 
microscopy of cells stained with anti-E-tubulin for microtubule staining showing induction of 
monoastral spindles following treatment with Arry-520 in U2OS cells. U2OS cells previously 
selected to be resistant to STLC due to expression of either Eg5(D130A) or Eg5(L214A) were 
also capable of forming normal bipolar spindles in the presence of Arry-520. In stark contrast 
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to Eg5(D130A) expressing U2OS cells, the Eg5(L214A) expressing cells were still sensitive 
to ispinesib as shown by the presence of monoastral spindles. Scale bar = 10 Pm. c) Cells 
were treated with either 10 PM STLC (solid black bars), 10 nM Arry-520 (dark gray bars) or 
10 nM ispinesib (light gray bars) for 8 h and then were fixed and stained for 
immunofluorescence microscopy as in panel b. The percentage of monoastral spindles from 
the total number of mitotic cells was then quantified. 
 
Figure 3. Duration of mitosis and colony formation of U2OS cells expressing either 
Eg5(D130A) or Eg5(L214A) STLC resistant clones in the continuous presence of STLC, Arry-
520 or ispinesib. After addition of 10 PM STLC, 10 nM Arry-520 or 10 nM ispinesib cells 
were recorded for 16 h by time-lapse video microscopy and the time that each cell spent in 
mitosis was scored. The time of each cell that successfully completed mitosis is plotted 
against the number of cells (number in parenthesis at each condition). b) Cells (2k) following 
seeding were treated with either 10 PM STLC, 10 nM Arry-520 or 10 nM ispinesib and 
allowed to proliferate for 10 days. Cells were then fixed and stained with crystal violet. c) 
U2OS cell expressing either Eg5(D130A) or Eg5(L214A) were plated at a density of 17,000 
cells per well in 24-
Arry-520, or 10 nM Ispinesib. Following treatment for four days, cells were fixed with 4% 
paraformaldehyde and stained with 0.5% Crystal Violet. Shown are representative images of 
two wells from experiments performed in triplicate. d) Quantitation of c) as per absorbance at 
595 nm normalized relative to the untreated cells.  *p < 0.05.  
 
Figure 4. Flexibility of Arry-520 and ispinesib in the allosteric binding site. Arry-520 binding 
in WT Eg5 (a), D130A (b) and L214A(c) Eg5 mutants. Ispinesib (ISP) binding in WT (a’), 
D130A (b’) and L214A (c’) mutants. The spatial position of wild type residues (labeled in 
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black) and mutations (labeled in red) is illustrated as sticks. Structural flexibility (shown in 
cyan) of ispinesib is similar in both wild type Eg5 and the Eg5(L214A) mutant, but higher in 
D130A. Arry-520 is less flexible in the wild type and more so in the Eg5(L214A) and 
Eg5(D130A) mutants. The structural dynamics of Arry-520 and ispinesib over the course the 
simulations are illustrated as cyan lines. The final conformations of the drugs are illustrated as 
cyan sticks. Rotations of the indicated bonds (indicated by red asterisks) take place around the 
bond between d) the 2,5-difluorophenyl group and the 1,3,4-thiadiazole ring in Arry-520 and 
e) the quinazolin-4-one ring and the isopropyl group in ispinesib. f) Bond angle flexibility in 
wild type Eg5 is shown in black, in blue for the Eg5(D130A) mutant and in red color for the 
Eg5(L214A) mutant.  
 
 
 
 
 
 
 
 




